MYGN Nov 2024 24.000 call
| Previous Close | 5.10 |
| Open | 5.10 |
| Bid | 2.60 |
| Ask | 4.90 |
| Strike | 24.00 |
| Expire Date | 2024-11-15 |
| Day's Range | 5.10 - 5.10 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 73 |
ZacksHere's Why Myriad Genetics (MYGN) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
GlobeNewswireMyriad Genetics to Share New Data Highlighting Genetic Testing Advancements at 2024 National Society of Genetic Counselors Annual Conference
MyRisk®, FirstGene®, Prequel®, and Foresight® studies among 10 datasets to be shared by MyriadSALT LAKE CITY, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it will showcase 10 studies highlighting its advancements in oncology and reproductive genetic testing at the National Society of Genetic Counselors (NSGC) 43rd Annual Conference, which will take place from Sept. 17-21, 2024, in New Orleans, LA. The
ZacksShould You Continue to Retain MYGN Stock in Your Portfolio?
Myriad Genetics is advancing with strategic priorities, and bringing new products and upgrades to the market, positively influencing investors' sentiment.
